<SEC-DOCUMENT>0001213900-23-056022.txt : 20230711
<SEC-HEADER>0001213900-23-056022.hdr.sgml : 20230711
<ACCEPTANCE-DATETIME>20230711060357
ACCESSION NUMBER:		0001213900-23-056022
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20230711
FILED AS OF DATE:		20230711
DATE AS OF CHANGE:		20230711

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		231081159

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea181612-6k_immuron.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>THE
SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the Month of July 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commission
File Number: 001-38104</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>IMMURON
LIMITED</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Name
of Registrant)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Level
3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Address
of principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Yes &#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IMMURON
LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>EXPLANATORY
NOTE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Immuron
Limited (the &ldquo;Company&rdquo;) published one announcement (the &ldquo;Public Notices&rdquo;) to the Australian Securities Exchange
on July 11, 2023 titled:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Letter
    to Shareholders&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">A copy of
the Public Notice is attached as an exhibit to this report on Form 6-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
report on Form 6-K (including the exhibit hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange
Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities
Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EXHIBITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; width: 8%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    </B><BR>
    <B>Number</B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: bottom; width: 91%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ea181612ex99-1_immuron.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter to Shareholders</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SIGNATURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON
    LIMITED</B></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_001.jpg" ALT=""></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    July 11, 2023</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Phillip Hains</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip
    Hains</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea181612ex99-1_immuron.htm
<DESCRIPTION>LETTER TO SHAREHOLDERS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Letter to Shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Highlights:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Ateria has launched Juvia&trade; containing
breakthrough natural ingredient ERME&trade; in Australia</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>New clinical study is underway with the NHS
in Swansea, Wales in people diagnosed with IBS due to malfermentation of carbohydrates in the gut.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Melbourne, Australia, July 11, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Immuron Limited Shareholders (ASX: IMC; NASDAQ:
IMRN),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron is pleased to announce that Ateria Health
Australia Pty Ltd, a subsidiary of Ateria Health Limited (&ldquo;Ateria&rdquo;), has launched Juvia&trade; in Australia<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Immuron
completed settlement of a strategic investment in Ateria on 16 November 2022 (17.5% shareholding). Ateria is a UK based biotech company
that develops and distributes supplements for overall health, including products that strengthen the gut microbiome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In response
to shareholder requests for an update on Ateria activities, the Company is sharing the pertinent parts of an update recently provided
to Ateria shareholders by </FONT>Ateria&rsquo;s CEO, Neil Wickers:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&ldquo;Our first brand Juvia&trade; launched
in the UK last year targeting people who suffer from irritable bowel syndrome (IBS). It contains our breakthrough patent pending natural
ingredient ERME&trade;. We are selling direct to consumer via our website www.juvia.me. The consumer response has been phenomenal, and
we have received 100&rsquo;s of life changing testimonials. On our page (https://au.trustpilot.com/review/juvia.me) of the independent
review site Trustpilot, we are rated &ldquo;excellent&rdquo; and the leading UK lifestyle magazine has awarded us their reader recommended
accreditation. We are seeing sales in the UK grow month-on-month and we are pleased with the momentum. We continually refine our digital
marketing strategy, and we now have a much deeper understanding of how to identify, attract and convert target customers.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Juvia&trade; Australia</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>We are excited to announce we are launching
in Australia this week. Our Australian website www.juvia.me is now live and we are fulfilling orders with free standard shipping from
our logistics partner in Melbourne. Given that we have a loyal following in Australia with many ordering via our UK site we expect sales
to inform our Australian launch. We will be supporting launch with Google advertising, social media advertising on Facebook, Instagram
and TikTok and PR in local and national media.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_003.jpg" ALT="" STYLE="height: 100px; width: 780px"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><I><IMG SRC="ex99-1_002.jpg" ALT=""></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>New Clinical Study Underway</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>We now have 14 studies on ERME&trade; in humans,
horses, dogs and birds all showing consistent results. We have shown that ERME&trade; improves the diversity of the microbiome (improving
its capability and resilience), increases good bacteria (particularly those that produce butyrate, which is important for the cells of
the gut wall, as well as those that have an anti-inflammatory response), reduces toxins and improves symptoms of IBS.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Our latest study is with the NHS in Swansea,
Wales, and will look at people diagnosed with IBS due to malfermentation of carbohydrates in the gut. The first patients have been recruited
and results should be available later this year.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>We are also in the planning stages for an observational
study in Melbourne later this year with Dr Harry Frydenberg, one of Australia&rsquo;s leading gastric surgeons, as Principal Investigator.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron continues to develop plans for launch
of Travelan<SUP>&reg;</SUP> in UK / Europe including regulatory pathways, options for label claims, import requirements, distribution
requirements and supply chain planning. Ateria is launching Juvia&trade; in Australia direct to consumer under the Australia New Zealand
Food Standards Code. Immuron is assisting Ateria with evaluating the requirements for including Juvia&trade; in the Australian Register
of Therapeutic Goods as a complementary medicine. This is a precursor for launch of Juvia&trade; in the pharmacy sales channel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you for your support.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex99-1_004.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Steven Lydeamore</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This release has been authorised by the directors
of Immuron Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><IMG SRC="ex99-1_003.jpg" ALT="" STYLE="height: 100px; width: 780px"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B><IMG SRC="ex99-1_002.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contact Information:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Steven Lydeamore</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ph: +61 (0)3 9824 5254</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">info@immuron.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">https://www.immuron.com.au/form/contact-us/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Travelan<SUP>&reg;</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Travelan<SUP>&reg;
</SUP>is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers&rsquo; diarrhea,
<FONT STYLE="background-color: white">a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce</FONT>.
Travelan<SUP>&reg;</SUP> is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when
taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers&rsquo; diarrhea.
In Australia, Travelan<SUP>&reg;</SUP> is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated
to reduce the risk of Travelers&rsquo; Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan<SUP>&reg;</SUP> is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers&rsquo;
Diarrhea. In the U.S., Travelan<SUP>&reg;</SUP> is sold as a dietary supplement for digestive tract protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>About Travelers&rsquo; diarrhea</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Travelers&rsquo; diarrhea
is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating,
and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic <I>Escherichia coli</I> (ETEC) playing a dominant
causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella
spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused
with travelers&rsquo; diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>About Immuron</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Immuron Limited (ASX:
IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal
antibodies for the treatment of inflammatory mediated and infectious diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">For more information
visit: http://www.immuron.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FORWARD-LOOKING STATEMENTS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts. Forward-looking statements are based on management&rsquo;s current expectations
and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock
value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties
relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in
our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_003.jpg" ALT="" STYLE="height: 100px; width: 780px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !$ #H# 2(  A$! Q$!_\0
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I !1110 4444 %0M;PLVXQJ3_ #HHH AC46]OMC& .F><9 JY110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* 0P# 2(  A$! Q$!_\0
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MH/Q7F\]8=;@0QL<>?",%?JO?\*V?$_Q+LM*(M]+5+VX*@F3=^[3(XZ=36?\
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MI[9:3FXL8+@@ R1JY [9&:\[T[XG32^(197\%M!:!W#S9.5"@G^@KO\ 2_\
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M*OOJG_H0KC/A!_R%M2_ZX+_Z%7:?$/\ Y$F^_P" ?^A"N+^$'_(4U+_K@O\
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M4H-6TNWOK=@T<R!N.Q[CZ@TL8KTZ<EM;_(,([5*D7O?_ #+E>&?$S_D=Y_\
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98Y&&&D8EG/XFM:BBLY2<G=LTC%15DC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R +<# 2(  A$! Q$!_\0
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4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex99-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !4 MX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHKD_'OC70/AMX'\8_$/Q5<26GAGP+X7U[Q?X@N88O/GAT;PYI=UJ^I26\&Y#
M/<"SLYO(MU96GFV1*0SBJA"=6<*5.$JE2I.%.G""<ISJ5)PITX0BKN4YSG"$
M8I-RE.,4FVA2E&$92E)1C&,I2E)J,8QC%RE*4FTE&,8RE)MI*,9-M)-KYY_:
MV_;6^ ?[%G@B#QE\:O$TMM<:H[P^&/!7A^*UU/QOXLEA9!=MHNC7%[I\"V-@
MKJU_K&JW^F:/;2R6NGF_?5M1TO3K[^<WXE?\'(_Q1FUVY'PC^ /P\TGP[')Y
M=J/B!J/B?Q5JMS&F]3<R7.@:OX&M[<W/[N86G]G3&SR]N;N]PMTW2_"/PA\)
MOVA;+XI_\%>/^"G&J6^H_!P^)-5\._ ;X+W#7&H:!K5KX<O[S1-)L=.T!9+,
M^*K:'4K*^\-^$?"I%M9ZW?Z7XF\9>._/MIM0U.>MHW_!8?7/BK)J'@/X)?\
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MXKOM!T^+3[2]U6X$DCZEXF\27]A83:A*LIB>]:ZD201D'^?GX->&_P#@JO\
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MK3G%N2Y9S****\@],**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'&)/-FLYO$5AJ5]# R*55WM-+F,IE:.)K5;B,N6=$?\ 4&OD']NWX6Q_%_\
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M!NC_ +,WQKT^]L?$G[-?Q8U/XB? 3Q5+B]M/#_\ ;E_IVJ>._AMKT=B9S=^
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M7)_9\C<#9NWYV\XV\@9&1S7[5F+MXA<;-7;_ .)=L.]6VW_QC.$3;>[?O_\
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M%-Q K%H?#?@OQ+M<J/N0W>OV.@:?*S'A=EV5SU8#FOX['OYI.9)))/=WD?\
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M8#$2]I6R[,,#A\RP$JO,YNM3H5YT*N&K.;<W4PF+H7FY5%&%6=2I5_C0\ >
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M3_%M;4N%I_X>):*_]*RN)_K''Z9G@M+>KQC#_%PI7?\ Z1G$C^T*BOXS8_\
M@X1_;/7&_P #?L^R<@G_ (H[QNO&.1\OQ)[]<_TJY'_P<+_MB+]_X<_L^2=>
MOA3QXOT'R_$SM_\ KK)_13\7EM@^&GZ<3X-?GEZ-E],?P2>^-XLCZ\(XY_\
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MO>$F7]I/6XP?X;7P5\,+(#G/!L_!$##TR&S773^B!XC2_B9[P92[VQN<U?\
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M.^:_S1)]:U>Y?S+C4KV=\YWRW$KMGUW,Q.?QJ,:KJ@X&HWRCGA;N=1SU&%D
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M@GB;.)7]50CA5]UCPL3]+GQUQ%^3B3)L)?IA.$<BC;T>(EC'Z7O\S^I[6/\
M@XOM S#0_P!FO3 G.V34_BU>3.O7!,-I\.( _;($Z?[PKSG4_P#@XE^),@8Z
M1\$?AI9'G8+_ %/Q?K 4YXW-:W.B[L#&<*F>2".@_FGHKV\/]'GP:PUN7@;
MUK=<7F.?8J_K[3.::?W+T/ Q/TFO';%-\WB'F%"_3!95PY@TO3V615&O_ F?
MT$ZW_P '!W[4%YN&D>"_@AHZDG:8_!_C>_E4>A>]\?O$6]"8 .<E3@BO,]7_
M ."[_P"V?J 86?B'P7HA(P#I/PYT27:?51KJZQ^&_<.F<\U^(5%>WAO!GPGP
MEO8^'G"FFSK99+%OYO&8_%7^:=^Q\_BO'7QGQK?M_%#C/7=4,VC@E\E@<MP=
MODU;HS]9]:_X+._MVZPQ8?'+5M/1L[HM*\"_#'3EP<C"O#X26=,=04E0^]>9
MZK_P5/\ VU=7#BY_:&^+$9;.6TSQ"-"//]T:*+%8_P#@"C':OSDHKWL-X?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex99-1_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 +$# 2(  A$! Q$!_\0
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LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
